在胰腺癌的治疗发展
Z Ian Hu1, Eileen M O'Reilly2,3
1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nature reviews. Gastroenterology & hepatology
|October 5, 2023
概括
胰腺癌 (PDAC) 仍然是一个致命的恶性瘤. 本综述涵盖了治疗的最新进展,包括新生物标志物和向治疗,如PARP抑制剂和免疫疗法,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 翻译医学是一种翻译医学.
背景情况:
- 胰腺管腺癌 (PDAC) 发病率正在上升,这在人类瘤学中构成了重大挑战.
- 尽管对PDAC生物学有广泛的了解,但改善患者结果的临床翻译是有限的.
- 迫切需要推进这种侵袭性癌症的治疗策略.
研究的目的:
- 审查胰腺管道腺癌 (PDAC) 的最新进展和改变实践的临床试验.
- 讨论正在进行的研究,新型生物标志物和临床试验设计,旨在完善PDAC的护理标准.
- 突出新兴的治疗领域和胰腺癌研究的未来方向.
主要方法:
- 关于PDAC近期进展和临床试验的综合文献综述.
- 对治疗失败的分析和正在进行的研究工作.
- 讨论当代的研究领域,包括多基 (ADP-ribose) 聚合酶抑制剂,KRAS向疗法和免疫疗法.
主要成果:
- 了解PDAC生物学方面的进展尚未完全转化为改善患者存活率.
- 几种治疗策略,包括多基 (ADP-ribose) 聚合酶抑制剂,KRAS向疗法和免疫疗法,都显示出有前途.
- 新型生物标志物和创新的临床试验设计对于完善PDAC治疗至关重要.
结论:
- 将PDAC研究转化为临床实践仍然是一个重大障碍.
- 向疗法和免疫疗法是未来PDAC治疗的有希望的途径.
- 持续的研究和改进的临床试验设计对于在未来十年推进胰腺癌治疗至关重要.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
99
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
99
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K